G
Gregory Kaltsas
Researcher at National and Kapodistrian University of Athens
Publications - 379
Citations - 18111
Gregory Kaltsas is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Neuroendocrine tumors & Medicine. The author has an hindex of 63, co-authored 342 publications receiving 15275 citations. Previous affiliations of Gregory Kaltsas include Tufts Medical Center & University of Warwick.
Papers
More filters
Journal ArticleDOI
Metabolic syndrome: definitions and controversies
TL;DR: It is suggested that diagnosis, prevention and treatment in children and adolescents should better focus on established risk factors rather than the diagnosis of MetS, because of its alarmingly increasing prevalence.
Journal ArticleDOI
Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
Adam H. Balen,G. S. Conway,Gregory Kaltsas,Kitirak Techatraisak,Patrick J. Manning,Christine West,Howard S. Jacobs +6 more
TL;DR: Describing data from the largest reported series of women with PCOS enables the development of a management-orientated approach to the syndrome.
Journal ArticleDOI
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
Massimo Falconi,Barbro Eriksson,Gregory Kaltsas,Detlef K. Bartsch,Jaume Capdevila,Martyn Caplin,Beata Kos-Kudła,Dirk Jan Kwekkeboom,Guido Rindi,Günter Klöppel,Nicholas Reed,Reza Kianmanesh,Robert T. Jensen +12 more
TL;DR: The ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatics with Functional and non-functional tumours is published.
Journal ArticleDOI
The diagnosis and medical management of advanced neuroendocrine tumors.
TL;DR: Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance, and therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails.
Journal ArticleDOI
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
Martyn Caplin,Eric Baudin,Piero Ferolla,P.L. Filosso,Mariano García-Yuste,Eric Lim,Kjell Öberg,Giuseppe Pelosi,Aurel Perren,Roberta Elisa Rossi,Roberta Elisa Rossi,William D. Travis,Detlief Bartsch,Jaume Capdevila,Frederico Costa,Jarosław B. Ćwikła,Wouter W. de Herder,Gianfranco Delle Fave,Barbro Eriksson,Massimo Falconi,Diego Ferone,David J. Gross,Ashley B. Grossman,Tetsuhide Ito,Robert T. Jensen,Gregory Kaltsas,Fahrettin Kelestimur,Reza Kianmanesh,Ulrich Knigge,Beata Kos-Kudła,Eric P. Krenning,Emmanuel Mitry,Marianne Nicolson,Juan Manuel O'Connor,Dermot O'Toole,Ulrich Frank Pape,Marianne Pavel,John Ramage,Eric Raymond,Guido Rindi,Andrea Rockall,Philippe Ruszniewski,Ramon Salazar,Aldo Scarpa,Eva Sedlackova,Anders Sundin,Christos Toumpanakis,Marie Pierre Vullierme,Wolfgang Weber,Bertram Wiedenmann,Zeng Zheng-Pei +50 more
TL;DR: PCs are complex tumors which require a multidisciplinary approach and long-term follow-up, and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC.